两项精准肿瘤学试验中胚系变异可操作性与偶然发现的评估
研究纳入MOSCATO与MATCHR两项精准肿瘤学试验的288例晚期癌症患者,采用250个癌症相关基因panel进行胚系DNA测序并在肿瘤分子委员会讨论。12.5%患者检出胚系致病性变异,多归为ESCAT X(63.9%),2%为可操作变异(ESCAT I-A/II-A),7.3%有癌症易感基因偶然发现。
要点
- 288例晚期癌症患者中12.5%检出胚系致病性变异,多数为ESCAT X(63.9%)。
- 仅2%患者携带可操作变异(ESCAT I-A/II-A)。
- 7.3%患者有癌症易感基因偶然发现,其中2.4%为极高风险。
核心结论
- 研究强调胚系测序在识别可操作变异中的意义,并指出精准肿瘤学试验中需改进变异解读与检测前咨询计划。
研究设计与样本
- 研究纳入MOSCATO(NCT01566019)和MATCHR(NCT02517892)两项精准肿瘤学试验的288例晚期癌症患者,采用250个癌症相关基因panel进行胚系DNA测序,结果在肿瘤分子委员会讨论。
主要发现
- 肺癌占36.8%,前列腺癌占18.4%,乳腺癌占17.7%,为最常见的肿瘤类型。
- 12.5%的患者检出胚系致病性变异,其中63.9%归类为ESCAT X。
- 2%的患者携带可操作变异(ESCAT I-A/II-A)。
- 7.3%的患者在癌症易感基因中检出致病性变异作为偶然发现,其中2.4%具有极高风险潜力,需强制进行肿瘤遗传咨询。
- 21.9%的患者至少有一个VUS。
关键数值与推荐
- 胚系致病性变异按ESCAT分类进行归类。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: High-throughput sequencing techniques have revolutionized oncology. Paired germline-tumor DNA analysis has emerged as a comprehensive strategy to uncover actionable alterations in advanced cancer patients (ACP) enrolled in precision oncology trials. However, challenges persist in variant interpretation and managing incidental germline findings. METHODS: We conducted a study involving 288 ACP from MOSCATO (NCT01566019) and MATCHR (NCT02517892) trials to assess germline variants impacting cancer-related genes. Germline DNA sequencing was performed using a panel of 250 cancer-related genes, and the results were discussed during tumor molecular board sessions. RESULTS: Germline pathogenic variants (PV) were classified according to the ESCAT classification. Lung cancer (36.8 %), followed by prostate (18.4 %) and breast cancer (17.7 %), comprised the most prevalent tumor types. PVs were found in 12.5 % of patients. Most PVs were classified as ESCAT X (63.9 %), highlighting limited therapeutic actionability. Notably,2 % of patients had actionable variants (ESCAT I-A/II-A). Incidental findings included 7.3 % of patients with PVs in cancer-predisposition genes, with 2.4 % having very high-risk potential, necessitating mandatory oncogenetic counseling. Nearly one in five patients (21.9 %) had at least one VUS. DISCUSSION: Our study underscores the significance of germline sequencing in identifying actionable alterations and the need for improved variant interpretation as well as pretest counseling plans in precision oncology trials.
引用
- Ibrahim MB, Adnani Y, Clément GJ, et al. Assessing actionability and incidental findings of germline variants in two precision oncology trials. Eur J Cancer. 2024. PMID: 39154486. doi:10.1016/j.ejca.2024.114256
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。